Travoprost

Ophthalmic
Open-angle glaucoma, Ocular hypertension
Adult: As 0.003% or 0.004% solution: Instill 1 drop in the conjunctival sac of the affected eye(s) once daily, preferably in the evening.
Child: ≥3 years As 0.003% solution: Same as adult dose.

Patients with risk factors of cystoid macular oedema, history of intraocular inflammation (e.g. uveitis, iritis). Aphakic, and pseudophakic patients with torn posterior lens capsule. Children. Pregnancy and lactation. Patient Counselling Remove contact lenses prior to ophth administration and reinsert after 15 minutes. This drug may cause transient effects on vision, if affected, do not drive or operate machinery.

Significant: Iris hyperpigmentation, macular oedema, bacterial keratitis, changes in length, thickness, pigmentation or number of eyelashes. Eye disorders: Ocular hyperaemia, cataract, conjunctivitis, decreased visual acuity, blurred vision, blepharitis, corneal staining, ocular inflammation, photophobia, crusting of eyelid margin, foreign body sensation in eyes, deepening of eyelid sulcus, eye tearing, pain in the eye, dry eye, ocular pruritus, ocular discomfort.

Travoprost is a highly selective full agonist prostaglandin F₂α analogue with high affinity to prostaglandin FP receptor. It reduces intraocular pressure by increasing outflow of aqueous humour through trabecular meshwork and uveoscleral pathways.
Onset: Approx 2 hours.
Absorption: Absorbed through the cornea. Time to peak plasma concentration: Within 1-2 hours.
Metabolism: Metabolised in the cornea via hydrolysis by esterases to active free acid; further metabolised systematically into inactive metabolites via β-oxidation of the α-carboxylic acid chain; oxidation of 15-hydroxyl moiety, and reduction of the 13, 14 double bond.
Excretion: Via urine (<2% as free acid). Elimination half-life: 45 minutes.

Ophthalmic: Store between 2-25°C.

Antiglaucoma Preparations

S01EE04 - travoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.